- Home
- OSUR vs LYEL Comparison
OSUR vs LYEL Comparison
Compare OSUR & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- LYEL
- Stock Information
- Founded
- OSUR 2000
- LYEL 2018
- Country
- OSUR United States
- LYEL United States
- Employees
- OSUR N/A
- LYEL N/A
- Industry
- OSUR Medical/Dental Instruments
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- OSUR Health Care
- LYEL Health Care
- Exchange
- OSUR Nasdaq
- LYEL Nasdaq
- Market Cap
- OSUR 223.0M
- LYEL 207.7M
- IPO Year
- OSUR 1986
- LYEL 2021
- Fundamental
- Price
- OSUR $3.00
- LYEL $8.69
- Analyst Decision
- OSUR Hold
- LYEL Sell
- Analyst Count
- OSUR 1
- LYEL 2
- Target Price
- OSUR $3.00
- LYEL $20.00
- AVG Volume (30 Days)
- OSUR 804.6K
- LYEL 249.1K
- Earning Date
- OSUR 08-05-2025
- LYEL 08-06-2025
- Dividend Yield
- OSUR N/A
- LYEL N/A
- EPS Growth
- OSUR N/A
- LYEL N/A
- EPS
- OSUR N/A
- LYEL N/A
- Revenue
- OSUR $161,626,000.00
- LYEL $65,000.00
- Revenue This Year
- OSUR N/A
- LYEL N/A
- Revenue Next Year
- OSUR $6.20
- LYEL N/A
- P/E Ratio
- OSUR N/A
- LYEL N/A
- Revenue Growth
- OSUR N/A
- LYEL N/A
- 52 Week Low
- OSUR $2.36
- LYEL $7.65
- 52 Week High
- OSUR $4.92
- LYEL $45.42
- Technical
- Relative Strength Index (RSI)
- OSUR 54.60
- LYEL 44.96
- Support Level
- OSUR $2.78
- LYEL $8.96
- Resistance Level
- OSUR $3.03
- LYEL $10.96
- Average True Range (ATR)
- OSUR 0.13
- LYEL 2.14
- MACD
- OSUR 0.01
- LYEL -0.17
- Stochastic Oscillator
- OSUR 58.93
- LYEL 16.91
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.